EXAS

Congress Trades

Name	Value	Action	Amount Range	Price	Current Price
Kevin HernRepublican $8.0k SellMar 24, 2026 $1k-$15k -- --

News

proactiveinvestors.comAbbott Labs shares fall as earnings beat offset by Exact Sciences acquisition dragproactiveinvestors.comApr 16

defenseworld.net96,685 Shares in Exact Sciences Corporation $EXAS Purchased by Capricorn Fund Managers Ltddefenseworld.netApr 6

defenseworld.netExact Sciences Corporation $EXAS Shares Sold by Exchange Traded Concepts LLCdefenseworld.netApr 4

defenseworld.netFNY Investment Advisers LLC Buys Shares of 28,500 Exact Sciences Corporation $EXASdefenseworld.netApr 3

defenseworld.netBanque Pictet & Cie SA Lowers Position in Exact Sciences Corporation $EXASdefenseworld.netApr 3

Trade EXAS

About Exact Sciences Corporation

Exact Sciences Corporation specializes in developing and distributing cancer screening and diagnostic tools across the United States and internationally. Their key product, Cologuard, is an innovative, non-invasive test that analyzes stool-based DNA to identify specific DNA and hemoglobin biomarkers indicative of colorectal cancer and precancerous conditions. The company's extensive portfolio also includes the Oncotype DX family of gene expression tests, designed for breast, prostate, and colon cancers. Within this suite, the Oncotype Test provides detailed tumor profiling from tissue samples, assisting in treatment selection for individuals battling advanced, metastatic, refractory, or recurrent cancers. Furthermore, they offer the Oncotype DX AR-V7 Nucleus Detect Test, a liquid biopsy designed for advanced-stage prostate cancer patients, and Oncomap ExTra, which delivers a comprehensive biological insight into challenging, rare, or aggressive malignancies. Exact Sciences also provides COVID-19 testing services. Future initiatives involve enhancing Cologuard's performance characteristics and pioneering novel blood- and other fluid-based diagnostic tests. The company maintains important license agreements with the MAYO Foundation for Medical Education and Research and Hologic, Inc. Established in 1995, Exact Sciences Corporation's corporate headquarters are located in Madison, Wisconsin.

CEO: Kevin T. Conroy
IPO Date: Feb 1, 2001

Market Data

Open: $104.91
High: $104.91
Low: $104.91
Volume: 21.6M
Avg Volume: 2.5M
52W High: $104.98
52W Low: $38.81

Valuation

Market Cap: $20B
Enterprise Value: $22B
Dividend Yield: 0.00%

Financials

Free Cash Flow: $357M
Revenue: $3.2B
Net Income: $-208M
Cash: $956M
Debt: $2.5B

Events

EarningsFeb 13

EPS est. -0.10793 · actual -0.45